Research progress and patent intelligence analysis of the drugs for the treatment of myopiaLI Jing, ZHANG Jing625-637
The conflict of interest declaration system of FDA external experts:The inspiration for ChinaLIU Jing-wen, ZHANG Zheng, DONG Jiang-ping, XING Hua638-643
Policy analysis and comparison related to drug safety supervision during the"14th Five-Year Plan"periodTANG Xiang-yan, CAO Yong-fang, HE Hui644-650
General considerations for in vitro testing of oral solid preparations administered through nasogastric tubesMENG Yong-gang, HOU Peng, WANG Ya-min651-653
Biological activity determination of recombinant human interleukin-2 products using reporter gene assayDUAN Mao-qin, GUO Ying, LUO Qian-qian, YU Chuan-fei, FU Zhi-hao, XU Gang-ling, WANG Lan654-661
Research progress on the preparation and new technology strategy of compound active pharmaceutical ingredientsTONG Yu, LIAO Zheng-gen, JIANG Qie-ying, YANG Hui, ZENG Hui-ling, WEN Jia-hao, OUYANG Qi662-670
Research progress of the third-generation progesterone etonogestrelWANG Sha-sha, ZHANG Ke, CHEN Pan, ZHAO Chun-cao, CHEN Liang-kang, CHEN Jian-xing, PAN Feng, LI Fang, GUO Yi-lin, FENG Ling-lin671-677
Efficacy and safety of furmonertinib in osimertinib-resistant patients with advanced non-small cell lung cancer:16 casesSI Xiao-yan, WANG Han-ping, ZHANG Xiao-tong, WANG Meng-zhao, ZHANG Li678-681
Pharmacokinetics and bioequivalence of paracetamol suspension in Chinese healthy volunteersGUO Wei-yi, FENG Shi-yin, CAI Lin-rui, ZOU Qin, CHEN Zhuo, SU Xu, DU Dan, YU Qin682-687
The therapeutic effects and mechanism of isoorientin on dextran sodium sulfate-induced ulcerative colitis in miceYANG Lan-zhu, WANG Yong, YANG Jing-ya688-695